The University of Southampton
University of Southampton Institutional Repository

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

BACKGROUND: Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line immunochemotherapy with obinutuzumab than with rituximab. The aim of this secondary analysis was to evaluate the prognostic value of PET-CT responses after first-line immunochemotherapy in the GALLIUM study.

METHODS: GALLIUM is an open-label, parallel-group randomised, phase 3 trial, which recruited previously untreated patients with CD20-positive follicular lymphoma (grades 1-3a; disease stage III/IV, or stage II with largest tumour diameter ≥7 cm) who were aged 18 years or older and met the criteria for needing treatment. Eligible patients were randomly assigned in a 1:1 ratio to receive intravenous administration of obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1, then day 1 of subsequent cycles) or rituximab (375 mg/m2 on day 1 of each cycle), in six 21-day cycles with cyclophosphamide, doxorubicin, vincristine, and prednisone (known as CHOP; oral administration) followed by two 21-day cycles of antibody alone, or eight 21-day cycles cyclophosphamide, vincristine, and prednisone (known as CVP; oral administration), or six 28-day cycles with bendamustine, followed by maintenance antibody every 2 months for up to 2 years. The primary endpoint of the trial, investigator-assessed progression-free survival, has been reported previously. This secondary analysis reports PET and CT-based responses at end-of-induction therapy and explains their relation with progression-free and overall survival outcomes in patients with available scans. As per protocol, during the trial, PET scans (mandatory in the first 170 patients enrolled at sites with available PET facilities, and optional thereafter), acquired at baseline and end of induction (PET population), were assessed prospectively by investigators and an independent review committee (IRC) applying International Harmonisation Project (IHP) 2007 response criteria, and retrospectively by the IRC only applying current Lugano 2014 response criteria. IRC members (but not study investigators) were masked to treatment and clinical outcome when assessing response. The landmark analyses excluded patients who died or progressed (contrast enhanced CT-based assessment of progressive disease, or started next anti-lymphoma treatment) before or at end of induction. GALLIUM is registered at ClinicalTrials.gov, number NCT01332968.

FINDINGS: 1202 patients were enrolled in GALLIUM between July 6, 2011, and Feb 4, 2014, of whom 595 were included in the PET population; 533 (IHP 2007; prospective analysis), and 508 (Lugano 2014; retrospective analysis) were analysed for progression-free survival (landmark analysis). At end of induction, 390 of 595 patients (65·5% [95% CI 61·6-69·4]) achieved PET complete response according to IHP 2007 criteria, and 450 (75·6% [95% CI 72·0-79·0]) obtained PET complete metabolic response according to Lugano 2014 criteria. With a median of 43·3 months of observation (IQR 36·2-51·8), 2·5-year progression-free survival from end of induction was 87·8% (95% CI 83·9-90·8) in PET complete responders and 72·0% (63·1-79·0) in non-complete responders according to IRC-assessed IHP 2007 criteria (hazard ratio [HR] 0·4, 95% CI 0·3-0·6, p<0·0001). According to Lugano 2014 criteria, 2·5-year progression-free survival in complete metabolic responders was 87·4% (95% CI 83·7-90·2) and in non-complete metabolic responders was 54·9% (40·5-67·3; HR 0·2, 95% CI 0·1-0·3, p<0·0001).

INTERPRETATION: Our results suggest that PET is a better imaging modality than contrast-enhanced CT for response assessment after first-line immunochemotherapy in patients with follicular lymphoma. PET assessment according to Lugano 2014 response criteria provides a platform for investigation of response-adapted therapeutic approaches. Additional supportive data are welcomed.

FUNDING: F Hoffmann-La Roche.

Journal Article
1474-5488
1-13
Trotman, Judith
5c2747a4-0747-4e19-ab69-c656b8f70862
Barrington, Sally F.
fb047bda-27e7-4082-b741-c41ef52aa53c
Belada, David
2ab900df-f7d6-407a-87b6-1dad941ba538
Meignan, Michel
e98d4c56-e4b2-42e9-ba8e-74315db8c553
MacEwan, Robert
2d28de25-ed5f-4638-a4bf-1a5373027d5f
Owen, Carolyn
d82e8dd6-f7f2-47bb-ac9f-4d929068ad69
Ptáčník, Václav
132f836b-4475-4e50-be1d-53400faafe6d
Rosta, András
798490fe-025b-4255-a942-4cae589fb28a
Fingerle-Rowson, Günter R.
62fc6f29-16e5-4644-a51c-553ca6606ef9
Zhu, Jiawen
722daea0-e682-41fd-9cab-ace3ecda4820
Nielsen, Tina
6800997e-c4a1-4fa5-b90c-0aae00f6fe68
Sahin, Deniz
9f947e78-bf17-4ba0-978e-0bdad60fe2eb
Hiddemann, Wolfgang
0710f0bd-14f1-4840-9abd-2349f69e8677
Marcus, Robert E.
510f7421-a75d-4c26-a4b7-ac9c506174a1
Davies, Andrew
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
PET investigators from the GALLIUM study
Trotman, Judith
5c2747a4-0747-4e19-ab69-c656b8f70862
Barrington, Sally F.
fb047bda-27e7-4082-b741-c41ef52aa53c
Belada, David
2ab900df-f7d6-407a-87b6-1dad941ba538
Meignan, Michel
e98d4c56-e4b2-42e9-ba8e-74315db8c553
MacEwan, Robert
2d28de25-ed5f-4638-a4bf-1a5373027d5f
Owen, Carolyn
d82e8dd6-f7f2-47bb-ac9f-4d929068ad69
Ptáčník, Václav
132f836b-4475-4e50-be1d-53400faafe6d
Rosta, András
798490fe-025b-4255-a942-4cae589fb28a
Fingerle-Rowson, Günter R.
62fc6f29-16e5-4644-a51c-553ca6606ef9
Zhu, Jiawen
722daea0-e682-41fd-9cab-ace3ecda4820
Nielsen, Tina
6800997e-c4a1-4fa5-b90c-0aae00f6fe68
Sahin, Deniz
9f947e78-bf17-4ba0-978e-0bdad60fe2eb
Hiddemann, Wolfgang
0710f0bd-14f1-4840-9abd-2349f69e8677
Marcus, Robert E.
510f7421-a75d-4c26-a4b7-ac9c506174a1
Davies, Andrew
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af

Trotman, Judith, Barrington, Sally F., Belada, David, Meignan, Michel, MacEwan, Robert, Owen, Carolyn, Ptáčník, Václav, Rosta, András, Fingerle-Rowson, Günter R., Zhu, Jiawen, Nielsen, Tina, Sahin, Deniz, Hiddemann, Wolfgang, Marcus, Robert E. and Davies, Andrew , PET investigators from the GALLIUM study (2018) Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncology, 1-13. (doi:10.1016/S1470-2045(18)30618-1).

Record type: Article

Abstract

BACKGROUND: Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line immunochemotherapy with obinutuzumab than with rituximab. The aim of this secondary analysis was to evaluate the prognostic value of PET-CT responses after first-line immunochemotherapy in the GALLIUM study.

METHODS: GALLIUM is an open-label, parallel-group randomised, phase 3 trial, which recruited previously untreated patients with CD20-positive follicular lymphoma (grades 1-3a; disease stage III/IV, or stage II with largest tumour diameter ≥7 cm) who were aged 18 years or older and met the criteria for needing treatment. Eligible patients were randomly assigned in a 1:1 ratio to receive intravenous administration of obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1, then day 1 of subsequent cycles) or rituximab (375 mg/m2 on day 1 of each cycle), in six 21-day cycles with cyclophosphamide, doxorubicin, vincristine, and prednisone (known as CHOP; oral administration) followed by two 21-day cycles of antibody alone, or eight 21-day cycles cyclophosphamide, vincristine, and prednisone (known as CVP; oral administration), or six 28-day cycles with bendamustine, followed by maintenance antibody every 2 months for up to 2 years. The primary endpoint of the trial, investigator-assessed progression-free survival, has been reported previously. This secondary analysis reports PET and CT-based responses at end-of-induction therapy and explains their relation with progression-free and overall survival outcomes in patients with available scans. As per protocol, during the trial, PET scans (mandatory in the first 170 patients enrolled at sites with available PET facilities, and optional thereafter), acquired at baseline and end of induction (PET population), were assessed prospectively by investigators and an independent review committee (IRC) applying International Harmonisation Project (IHP) 2007 response criteria, and retrospectively by the IRC only applying current Lugano 2014 response criteria. IRC members (but not study investigators) were masked to treatment and clinical outcome when assessing response. The landmark analyses excluded patients who died or progressed (contrast enhanced CT-based assessment of progressive disease, or started next anti-lymphoma treatment) before or at end of induction. GALLIUM is registered at ClinicalTrials.gov, number NCT01332968.

FINDINGS: 1202 patients were enrolled in GALLIUM between July 6, 2011, and Feb 4, 2014, of whom 595 were included in the PET population; 533 (IHP 2007; prospective analysis), and 508 (Lugano 2014; retrospective analysis) were analysed for progression-free survival (landmark analysis). At end of induction, 390 of 595 patients (65·5% [95% CI 61·6-69·4]) achieved PET complete response according to IHP 2007 criteria, and 450 (75·6% [95% CI 72·0-79·0]) obtained PET complete metabolic response according to Lugano 2014 criteria. With a median of 43·3 months of observation (IQR 36·2-51·8), 2·5-year progression-free survival from end of induction was 87·8% (95% CI 83·9-90·8) in PET complete responders and 72·0% (63·1-79·0) in non-complete responders according to IRC-assessed IHP 2007 criteria (hazard ratio [HR] 0·4, 95% CI 0·3-0·6, p<0·0001). According to Lugano 2014 criteria, 2·5-year progression-free survival in complete metabolic responders was 87·4% (95% CI 83·7-90·2) and in non-complete metabolic responders was 54·9% (40·5-67·3; HR 0·2, 95% CI 0·1-0·3, p<0·0001).

INTERPRETATION: Our results suggest that PET is a better imaging modality than contrast-enhanced CT for response assessment after first-line immunochemotherapy in patients with follicular lymphoma. PET assessment according to Lugano 2014 response criteria provides a platform for investigation of response-adapted therapeutic approaches. Additional supportive data are welcomed.

FUNDING: F Hoffmann-La Roche.

Text
Gallium PET FINAL word document 181018 - Accepted Manuscript
Download (1MB)

More information

e-pub ahead of print date: 8 October 2018
Additional Information: Copyright © 2018 Elsevier Ltd. All rights reserved.
Keywords: Journal Article

Identifiers

Local EPrints ID: 425489
URI: https://eprints.soton.ac.uk/id/eprint/425489
ISSN: 1474-5488
PURE UUID: f4259e27-7fd8-4237-955f-7ea839e220c2

Catalogue record

Date deposited: 22 Oct 2018 16:30
Last modified: 23 Jul 2019 04:01

Export record

Altmetrics

Contributors

Author: Judith Trotman
Author: Sally F. Barrington
Author: David Belada
Author: Michel Meignan
Author: Robert MacEwan
Author: Carolyn Owen
Author: Václav Ptáčník
Author: András Rosta
Author: Günter R. Fingerle-Rowson
Author: Jiawen Zhu
Author: Tina Nielsen
Author: Deniz Sahin
Author: Wolfgang Hiddemann
Author: Robert E. Marcus
Author: Andrew Davies

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×